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Abstract
Iron deficiency anemia in pregnancy is a common and treatable condition that can
potentially affect pregnant women and their unborn fetus. In pregnant women, iron
deficiency anemia can lead to complications such as preterm labor, preeclampsia, and
even sepsis. In children, iron deficiency anemia could affect the neurodevelopment of the
fetus. This could potentially result in poor school performance, behavioral problems, or
cognitive deficits. In addition, iron deficiency anemia in pregnancy could lead to
intrauterine growth disturbances and potential fetal loss. In order to address this problem,
an outpatient intravenous iron infusion clinic has been implemented at a Women’s
Hospital to allow for access to an alternative approach to treatment. Oral iron
supplementation, the traditional treatment of iron deficiency anemia, is most often poorly
tolerated by patients. As a result, many patients exhibit poor compliance with treatment
for iron deficiency anemia. The goal of this quality improvement project is to provide
patients and providers with an effective and efficient outpatient alternative approach to
treat iron deficiency anemia in pregnancy.
Keywords: iron deficiency anemia, pregnancy, fetus, intravenous, iron infusion
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Introduction
Anemia is the most common condition worldwide and it is estimated that more than 1.5

billion people are affected (Api, Breyman, Çetiner, Demir, & Ecder, 2015). Iron deficiency
anemia accounts for approximately 50% of these cases (Api, Breyman, Çetiner, Demir, & Ecder,
2015). In pregnancy and postpartum patients, iron deficiency anemia is one of the most common
conditions (Bhavi & Jaju, 2017). The estimated global prevalence of iron deficiency anemia in
pregnancy is about 25% (Bhavi & Jaju, 2017). The prevalence is higher in developing countries
at 51% and lower in developed countries at 14% (Bhavi & Jaju, 2017). Iron deficiency anemia
could put pregnant women at increased risk for preterm labor, sepsis, and preeclampsia (Bhavi &
Jaju, 2017). Iron deficiency anemia is a treatable condition that when addressed, could make a
difference in the outcomes of obstetrical patients.
Iron deficiency anemia is not only a concern for the mother but also a potential problem
for the developing fetus. Anemia could cause intrauterine growth disturbances and even fetal loss
(Bhavi & Jaju, 2017). In addition, one recent study reports that iron deficiency anemia could
have an impact on fetal neurodevelopment (Basu, Kumar, Anupurba, et al., 2018). This could
potentially lead to children exhibiting poor school performance, developing behavioral problems,
and even developing cognitive deficits (Basu, Kumar, Anupurba, et al., 2018). As a result, iron
deficiency anemia is an important problem that needs to be addressed.
The current obstacles faced in the treatment of iron deficiency anemia include access to
care. Obstetrical patients with iron deficiency anemia are either treated with oral iron
supplements or intravenous iron sucrose. At the Women’s Hospital, it is challenging for these
patients to access the care they need. In order to receive an iron sucrose infusion, the patient is
required to essentially spend all day at the hospital. Based on the review of prior data, it takes
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about an average of 7 hours from start to finish to receive an iron infusion as an inpatient. The
steps of the current process include the following. First, the patients are admitted through the OB
Triage unit and then transferred to the High-Risk Antepartum unit. They could then potentially
wait several hours for the admission process, the medication to be delivered from the pharmacy,
the intravenous infusion of iron sucrose, and the discharge process. For some women, this is not
feasible and as a result, they decline the treatment that would be more effective for their
condition.
To address this problem, the Women’s Hospital is working towards the implementation
of an outpatient iron infusion clinic. It is proposed that this clinic will be part of the solution in
treating iron deficiency anemia in pregnancy. It will allow these women easier access to the care
they need and hopefully improve the outcomes of high-risk obstetrical patients with iron
deficiency anemia.
II.

Summary of the Literature
Anemia is one of the most prevalent conditions around the world. Iron deficiency anemia
is the most common form of anemia. It is also a very common medical condition among
pregnant women. The World Health Organization estimates that in 2011 there were
approximately 32 million pregnant women diagnosed with anemia and 50% of those cases
were attributed to iron deficiency (Govindappagari & Burwick, 2019). Iron deficiency
anemia screening should be conducted in the first trimester by checking the serum ferritin
and then monitoring the hemoglobin in the remaining two trimesters (Breymann, Honegger,
Hösli, & Surbek, 2017). If iron deficiency anemia is not addressed, it could potentially
negatively affect the outcomes of pregnancy. This could not only cause maternal
complications, but also fetal developmental concerns. To address this issue, it is proposed
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that the implementation of an outpatient iron infusion clinic will provide better access for
pregnant women and as a result, improve the outcomes of obstetrical patients with iron
deficiency anemia.
To conduct a thorough review of the literature, the database CINAHL Plus was utilized.
The search terms and Boolean phrases used were “iron deficiency anemia” AND pregnan*
AND “intravenous iron” OR “IV iron”. At first, the search yielded 46 results. Once the
limitations were set the results were condensed. The limitations used include the publication
year from 2015-present, full-text, scholarly peer-reviewed, pregnancy, and available in
English. The search results were then reduced to 25 articles. Of those search results, 18
articles were reviewed.
The articles were then screened for research conducted in the United States. Finally, 8
articles met all of the criteria for the purpose of this literature review. The most common
themes presented throughout the articles selected include the comparison of treatment with
oral iron and intravenous iron, maternal complications, and the outcomes of fetal
development.
Oral Iron vs. Intravenous Iron
The most common debate presented in the articles for the literature review is the
treatment of iron deficiency anemia with oral iron versus the administration of intravenous
iron. According to Govindappagari & Burwick 2019, supplementation with oral iron is the
first-line of treatment for pregnant women suffering from iron deficiency anemia
(Govindappagari & Burwick, 2019). The Institute of Medicine reports that the recommended
dose of elemental iron is 30-120mg daily for pregnant women (Govindappagari & Burwick,
2019). The issue, however, is that about 40-50% of pregnant women report side effects from
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oral iron consumption (Bhavi & Jaju, 2017; Govindappagari & Burwick, 2019; Sultan,
Bampoe, Shah, Guo, Estes, Stave, et al., 2019). The most common side effects reported from
oral iron are gastrointestinal in nature. These side effects include constipation, nausea,
vomiting, epigastric discomfort, bloating, diarrhea, heartburn, and dark stools (Bhavi & Jaju,
2017; Govindappagari & Burwick, 2019; Lewkowitz, Gupta, Simon, et al., 2019; Breymann,
Honegger, Hösli, & Surbek, 2017; Jose, Mahey, Sharma, Bhatla, Kriplani, Saxena, et al.,
2019; Sultan, Bampoe, Shah, Guo, Estes, Stave, et al., 2019). As a result of this intolerance
or noncompliance with treatment, providers may choose to consider treatment of iron
deficiency anemia with intravenous iron.
In comparison to oral iron, intravenous iron is more effective in the treatment of iron
deficiency anemia and usually, it is well tolerated. The only rare potential side effects of
intravenous iron include burning or swelling at the injection site, and hypersensitivity
reactions (Bhavi & Jaju, 2017; Lewkowitz, Gupta, Simon, et al., 2019; Breymann, Honegger,
Hösli, & Surbek, 2017; Govindappagari & Burwick, 2019). In addition to better tolerance,
treatment with intravenous iron has demonstrated a more rapid improvement in levels of
serum ferritin and hemoglobin in pregnant women at the time of delivery (Bhavi & Jaju,
2017; Lewkowitz, Gupta, Simon, et al., 2019; Sultan, Bampoe, Shah, Guo, Estes, Stave, et
al., 2019; Govindappagari & Burwick, 2019). One article states that pregnant women treated
with intravenous iron will achieve target hemoglobin levels after four weeks of treatment
(Govindappagari & Burwick, 2019). As a result of its efficacy, there is a decrease in the need
for blood transfusions during the peripartum and postpartum periods (Bhavi & Jaju, 2017;
Jose, Mahey, Sharma, Bhatla, Kriplani, Saxena, et al., 2019).

IMPLEMENTATION OF AN OUTPATIENT IRON INFUSION CLINIC

8

As for recommendations of treatment, researchers agree that intravenous iron should be
utilized especially in the cases of advanced gestational age, severe anemia, placenta previa,
Jehovah’s Witness patients, and lack of response to oral supplementation after two weeks
(Breymann, Honegger, Hösli, & Surbek, 2017; Govindappagari, & Burwick, 2019).
Although it has been proven to be safe and effective, intravenous iron remains underutilized
due to perceived risks and costs (Govindappagari, & Burwick, 2019; Juul, Derman, &
Auerbach, 2019). With more research and education, providers will be able to appreciate the
advantages of intravenous iron treatment for iron deficiency anemia of pregnancy.
Maternal Complications
If iron deficiency anemia is left untreated, it could potentially lead to maternal
complications. The more prevalent complications include symptoms associated with anemia
such as fatigue, headaches, dizziness, restless legs syndrome, and pica (Breymann,
Honegger, Hösli, & Surbek, 2017; Juul, Derman, & Auerbach, 2019). Iron deficiency anemia
of pregnancy is associated with higher rates of cesarean sections, greater need for blood
transfusions, and increased risks of preterm labor (Bhavi & Jaju, 2017; Lewkowitz, Gupta,
Simon, et al., 2019; Breymann, Honegger, Hösli, & Surbek, 2017; Govindappagari, &
Burwick, 2019; Juul, Derman, & Auerbach, 2019). Three articles report that iron deficiency
anemia of pregnancy is associated with increased risks of infection; poor wound healing, and
sepsis (Bhavi & Jaju, 2017; Breymann, Honegger, Hösli, & Surbek, 2017; Juul, Derman, &
Auerbach, 2019). Two articles discuss potential cardiovascular complications secondary to
iron deficiency anemia of pregnancy. These cardiac issues include preeclampsia,
cardiovascular distress, perinatal bleeding, placental abruption, and cardiac failure (Bhavi &
Jaju, 2017; Breymann, Honegger, Hösli, & Surbek, 2017; Juul, Derman, &Auerbach, 2019).
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Two articles discuss hormonal disturbances secondary to iron deficiency anemia of
pregnancy. These include decreased milk production in the postpartum period, and poor
maternal thyroid status (Breymann, Honegger, Hösli, & Surbek, 2017; Juul, Derman, &
Auerbach, 2019). Lastly, two articles discuss psychological symptoms as a result of iron
deficiency anemia. These symptoms include impaired cognition, depression, and reduced
mental capacities (Breymann, Honegger, Hösli, & Surbek, 2017; Sultan, Bampoe, Shah,
Guo, Estes, Stave, et al., 2019). In order to avoid potential maternal complications, it is
important to properly treat iron deficiency anemia during pregnancy.
Fetal Developmental Outcomes
Iron deficiency anemia of pregnancy could not only lead to maternal complications, but
also poor fetal developmental outcomes. Maternal iron deficiency could interfere with
normal intrauterine growth leading to low birth weights, preterm births, higher perinatal
mortality, more neonatal intensive care admissions, and disruptions in neural development
(Bhavi & Jaju, 2017; Breymann, Honegger, Hösli, & Surbek, 2017; Govindappagari, &
Burwick, 2019; Juul, Derman, & Auerbach, 2019; Lewkowitz, Gupta, Simon, et al., 2019).
Research suggests that iron deficiency anemia of pregnancy could potentially affect fetal
brain development, leading to cognitive deficits, poor scholastic performance, and behavioral
problems (Bhavi & Jaju, 2017; Basu, Kumar, Anupurba, et al., 2018; Juul, Derman, &
Auerbach, 2019). The hippocampus, which is especially vulnerable to iron deficiency, is
responsible for learning, memory, and cognition (Basu, Kumar, Anupurba, et al., 2018). In
addition, iron deficiencies can result in adverse effects on brain growth in terms of
myelination, neurotransmitter synthesis, and brain programming (Juul, Derman, & Auerbach,
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2019). To prevent these potential deleterious consequences, it is important to ensure proper
correction of maternal iron deficiency anemia.
In conclusion, the reviewed literature suggests that intravenous iron for the treatment of
iron deficiency anemia of pregnancy is a more efficacious and well-tolerated option. The
first-line treatment of oral iron supplementation, on the other hand, is more likely to result in
gastrointestinal adverse effects. The literature also emphasizes the importance of correcting
iron deficiency as it could result in maternal complications and/or negative fetal
developmental outcomes. It is proposed that the implementation of an outpatient intravenous
iron infusion clinic for obstetrical patients will have a positive impact on the rates of iron
deficiency anemia. By addressing the accessibility, increased costs, and disproving the
misconceptions of adverse effects, intravenous iron infusions could help decrease potential
maternal complications and improve fetal outcomes.
III.

Purpose/ PICO Question/ Objectives
A. PICO: “Does the implementation of an outpatient iron infusion clinic improve the
outcomes of high-risk obstetrical patients with iron deficiency anemia?”
B. Objectives
1. Improvement of anemia status.
2. Decreased need for blood transfusions during labor and postpartum.
3. Better patient satisfaction and access to care by decreasing the length of
stay for treatment.

IV.

Definition of Terms
A. Iron deficiency anemia - Iron deficiency anemia can be defined by any one of the
following findings:
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1. Serum ferritin < 30 ng/mL
2. Transferrin saturation < 19%, mostly used in patients for whom the ferritin
is thought to be unreliable due to an inflammatory state
3. Anemia that resolves upon iron administration
4. Absence of stainable iron in the bone marrow
(Uptodate, 2019)
B. Anemia of pregnancy - The World Health Organization (WHO) and the American
College of Obstetricians and Gynecologists (ACOG) define anemia in pregnancy
as follows:
1. First trimester – Hemoglobin < 11 g/dL
2. Second trimester – Hemoglobin < 10.5 g/dL
3. Third trimester – Hemoglobin < 10.5 to 11 g/dL
4. Postpartum – Hemoglobin < 10 g/dL
(Uptodate, 2019)
C. High-risk obstetrical patients - refers to women with an intrauterine pregnancy
that is considered high-risk according to the American College of Obstetricians
and Gynecologists, this includes preeclampsia, gestational diabetes, maternal
conditions complicating pregnancy, placenta previa, placenta accreta, placenta
percreta, coagulation disorders, acute fatty liver of pregnancy, ARDS, maternal
cardiac disease, autoimmune or hematologic disorders, severe pulmonary
hypertension, and pregnant women who are unstable and may require an organ
transplant. (ACOG, 2019)
D. Intravenous iron - refers to the intravenous form of iron replacement therapy; in
the case of our facility iron sucrose (Venofer) is utilized for obstetrical patients.
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Conceptual Underpinning and Theoretical Framework
The conceptual framework that will be utilized for the purpose of this DNP project is the

Donabedian model (Appendix H). This conceptual framework focuses on three aspects that
include structure, process, and outcome (McDonald, Sundaram, Bravata, et al., 2007). The
structure of this project entails determining how it would be best to establish and implement an
outpatient intravenous iron infusion clinic. The process would be the actual implementation of
the outpatient intravenous iron infusion clinic. Finally, the outcome would include the positive
outcomes of obstetrical patients that can receive intravenous iron infusions to treat iron
deficiency anemia of pregnancy.
In addition to the conceptual framework, a nursing theory will be utilized to guide this
DNP project. Lydia E. Hall’s theory of The Care, Core, and Cure will be applied as a guiding
principle for this project (Appendix H). Hall’s theory involves three independent but
interconnected circles of the care, the core, and the cure (Parker, 2005). The care refers to the
caregiver (Parker, 2005). The registered nurse administering the intravenous iron infusion would
be considered the care component. The core refers to the patient who needs medical care or
attention (Parker, 2005). In this case, the core is the obstetrical patient with iron deficiency
anemia. Finally, the cure refers to the medical treatment or attention given to patients (Parker,
2005). The intravenous iron treatment ordered by the provider would be considered the cure for
the purpose of this quality improvement project.
VI.

Methodology
A. Setting & Participants
1. Setting: Outpatient Infusion Clinic at a Women’s Hospital
2. Participants:

IMPLEMENTATION OF AN OUTPATIENT IRON INFUSION CLINIC
a) High-Risk Perinatal APRN Coordinator
•

Oversee the clinic as a contact person for any issues

•

Develop and implement clinic policy

•

Follow-up with patients scheduled at the clinic

b) Registered Nurse from Antepartum unit
•

Check-in and Check-out patients

•

Establish peripheral intravenous access

•

Order or verify medication from the pharmacy

•

Assess patient upon arrival and discharge

•

Scan patient wrist band and medication

•

Infuse iron over 30 minutes or as indicated by pharmacy

•

Flush and remove intravenous access once complete

•

Patient education on iron-rich diet & follow-up instructions

•

Discharge process

c) Nurse Manager
•

Manager overseeing the unit and registered nurse assigned

d) Attending Physician
•

Oversee the clinic and the fellow/resident assigned

e) Maternal Fetal Medicine Fellow or Resident
•

Determine which patients need to be seen in the clinic using
the intravenous iron algorithm

•

Input orders for patients

3. Hours of Operation: Mondays 8:00 AM – 12:00 PM

13
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4. Schedule/ Workflow:
7:00 AM - 7:45 AM: RN attends unit huddle and breakfast break
8:00 AM - 8:30 AM: RN reports to iron infusion clinic for set-up
8:30 AM: Patient #1
9:30 AM: Patient #2
10:30 AM: Patient #3
11:30 AM: Patient #4
12:00 PM: Outpatient iron infusion clinic closed
5. Technology: computer, phone, OB ultrasound monitor, blood pressure
monitor, thermometer, Cerner scheduling privileges/ access, new clinic to
be added to the scheduling application.
6. Supplies: patient recliners (3), OB ultrasound/ BP machines (3), privacy
curtains (5), IV poles & pumps (3), desk (1), office chair (1), omnicell
with supplies for infusions, medication omnicell with IV iron, and phone.
7. Training: Tasks and workflow of the clinic will need to be taught to the
registered nurse and nursing manager.
8. Potential Barriers/ Threats:
a) Difficulty with intravenous access
b) Access to supplies
c) Delay in receiving medication from the pharmacy
d) Late arrival of appointments
e) Time management & appointment overlap
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f) Waiting List for appointments/ too many patients for infusion
g) Ensuring the patient is financially cleared prior to appointment
h) Provider orders for infusion prior to appointment
B. Description of Approach and Project Procedures
The primary goal of this project is to successfully implement and establish an outpatient
intravenous iron infusion clinic for obstetrical patients within our facility. The goal is to be able
to treat pregnant women with iron deficiency anemia in an efficient outpatient setting. In doing
so, the goal is to improve the outcomes of high-risk obstetrical patients with iron deficiency
anemia.
Currently, high-risk pregnant women have to be admitted to the hospital for almost a
half-day in order to receive the intravenous iron infusion. According to the pre-data collected, on
average patients spend 6 hours and 51 minutes in the hospital for an iron infusion that only takes
30 minutes to administer. The goal is to be able to expedite this process and provide better access
to care. The iron infusions will be conducted on an outpatient basis in a clinic run by a registered
nurse. The patient would present at her given appointment time and check-in directly at the
clinic. The registered nurse would then check vitals and establish peripheral intravenous access.
The patient would then be given the iron infusion in a timely manner. Following infusion, the
intravenous access would be discontinued, vitals checked, and the patient discharged.
To prepare the medical staff for this new process, the nurses will be given an in-service
presentation during the unit huddle and the providers will be emailed an informational flyer. Any
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questions or concerns regarding the outpatient clinic will be directed to the High-Risk Perinatal
APRN Coordinator who will be overseeing the outpatient iron infusion clinic.
C. Protection of Human Subjects
1. Recruitment of subjects: High-risk obstetrical patients will be referred to
the clinic by their obstetricians.
2. Consent to the procedure: Patients will be asked to consent to treatment.
3. Participant benefits and risks: Patients will be educated on the benefits and
possible side effects associated with the intravenous iron infusion.
4. Safety: Material safety data sheets will be made available for medications
used in the clinic.
D. Data Collection
Data will be collected with the help of the Nursing Informatics Specialist at the
Women’s Hospital. She will pull reports demonstrating which obstetrics patients have
received iron infusions prior to the start of the clinic and after it is implemented. Then
with the help of the High-Risk Perinatal APRN Coordinator, the demographics, length of
stay, and hemoglobin levels of the patients will be reviewed and analyzed.
E. Data management and analysis plan
Data is available through the Cerner EMR system that the facility utilizes. Data
will be provided by the Nursing Informatics Specialist thus ensuring privacy and HIPAA
compliance. The data collected will then be analyzed by the researcher. The patients will
be assigned a unique identification number to compare results. The file will be password
protected and the computer used to analyze the data will be kept in a locked office.
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Results
The following results demonstrate the positive potential of the outpatient iron infusion

clinic. An iron infusion that initially took an average time of almost 7 hours, now takes
approximately 3 hours to complete outpatient. There is still room for improvement but the
preliminary data are supportive of the clinic’s efficacy and potential in treating iron deficiency
anemia in pregnancy.
Table 1: Pre-implementation data

IV Iron Infusions through OB Triage/ Antepartum Inpatient
PATIENT

DATE

ADMISSION TIME

DISCHARGE TIME TOTAL TIME (HOURS)

5245

11/04/20

13:34

20:30

6:56

4546

11/02/20

12:10

19:11

7:01

4695

10/14/20

11:05

19:23

8:18

5273

06/10/20

11:38

18:04

6:26

4006

06/08/20

8:25

15:00

6:35

5260

06/04/20

11:17

17:10

5:53

5273

06/04/20

9:53

17:09

7:16

5247

02/07/20

9:41

18:11

8:30

5234

01/17/20

13:00

19:07

6:07

4929

12/20/19

11:56

17:30

5:34

AVERAGE TIME
6:51
(HOURS)
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Table 2: Preliminary Post-implementation data

IV Iron Infusions through Outpatient Clinic
PATIENT

DATE

ADMISSION TIME

DISCHARGE TIME

TOTAL TIME (HOURS)

4695

10/26/20

10:30

13:30

3:00

4546

11/09/20

12:08

15:05

2:57

5245

11/09/20

12:41

15:15

2:34

AVERAGE TIME
2:50
(HOURS)

VIII.

Discussion
The Quality Improvement Project demonstrated the improvement of access to care for

patients with iron deficiency anemia in pregnancy. The project showed that the iron infusion
treatment length of stay decreased greatly when changed to an outpatient clinic setting. This
decreased length of stay will ultimately increase patient satisfaction and compliance. With
increased patient compliance, the outcomes of women and children affected by iron
deficiency anemia in pregnancy will improve.
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Although the data was only collected in regards to the patient length of stay, it
demonstrates that this advancement could potentially lead to improved patient outcomes. The
review of the literature shows the importance of treating iron deficiency anemia to reduce
the risks of complications in women and children as much as possible. The literature also
discusses how compliance is a major issue as many women are unable to tolerate oral iron
supplementation. By providing more efficient access to care through means of the outpatient
iron infusion clinic, patients will have access to a better treatment option for iron deficiency
anemia in pregnancy.
IX.

Limitations of the Project
Although this project has already shown great success, there are a few limitations that

need to be addressed. The first limitations encountered during this project were the
challenges that came along with the COVID-19 pandemic. Because this project took place at
a major hospital setting, the timeline was affected by the COVID-19 pandemic. The start date
of the outpatient iron infusion clinic was originally set for sometime in Summer 2020. Due to
administrative concerns, the clinic start date was postponed several times. The outpatient
clinic start date ended up being October 26, 2020. Due to the delayed start date, the data
collected was not comparable to the goal sample size. In addition, only data on length of stay
was collected due to timing constraints.
The next limitations of this project were the obstacles that presented from within the
facility. The administration of this facility went through several changes during this project.
For instance, the Director of the Women’s Hospital changed three times during this project.
This was a significant challenge because the High-Risk Perinatal APRN Coordinator and
preceptor of this project reports to the director. Each time the director changed, the project
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needed to be reintroduced and revised. In addition, there have been many challenges with the
pharmacy department. There is a significant delay in the availability of the iron sucrose for
the infusions. This delay could potentially cause a greater length of stay outpatient. The
infusion itself only requires 30 minutes to administer. If the medication is made more readily
available, the average length of stay could be further reduced.
Another potential limitation of this project is the sample population. The women referred
to the outpatient clinic are patients seen by the physicians of this facility. A more accurate
representation would include patients referred by obstetricians throughout the area.
X.

Implications for Advanced Practice Nursing
The implications for advanced nursing practice would be to guide those working in

obstetrics and maternal fetal medicine with alternative forms of treatment for anemia in
pregnancy. It would demonstrate the efficacy and promise of utilizing intravenous iron as
opposed to simply oral iron in the treatment of iron deficiency anemia in pregnancy. In
addition, this project may serve as a blueprint for other organizations to create a similar
outpatient iron infusion clinic for pregnant women. By doing so, patients would have better
access to care and improvement of iron deficiency anemia status. This would as a result lead
to better outcomes for mothers and their children.
XI.

Conclusions
In conclusion, the implementation of the outpatient iron infusion clinic has been

successful thus far. The length of stay from inpatient to outpatient treatment has been greatly
reduced. With this improvement comes increased patient satisfaction, better patient compliance
to treatment, decreased facility costs, reduced patient insurance costs, and improved patient
outcomes.
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Dissemination Plan
The next phase for this project would be dissemination by a poster presentation at a major

conference. Since this quality improvement project focuses on obstetrical patients, the goal
would be to present at a Nurse Practitioners in Women's Health (NPWH), Society of
Maternal Fetal Medicine (SMFM), or American College of Obstetricians & Gynecologists
(ACOG) conference in 2021 or 2022.
In addition, data will continue being collected to analyze both the length of stay and the
improvement of anemia status of patients. Once sufficient data has been collected, the goal
would be to submit for publication in an obstetrics journal or a publication for nurse
practitioners.
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IRB-20-0522
109049

IRB Approval Date:
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As a requirement of IRB Approval you are required to:
1) Submit an IRB Amendment Form for all proposed additions or changes in the procedures
involving human subjects. All additions and changes must be reviewed and approved by the
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from the approved protocol.
3) Utilize copies of the date stamped consent document(s) for obtaining consent from subjects
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4) Receive annual review and re-approval of your study prior to your IRB expiration date.
Submit the IRB Renewal Form at least 30 days in advance of the study’s expiration date.
5) Submit an IRB Project Completion Report Form when the study is finished or discontinued.
HIPAA Privacy Rule: Satisifed
Special Conditions:

N/A

For further information, you may visit the IRB website at http://research.fiu.edu/irb.
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C. Intravenous Iron Algorithm for Treatment

Iron Deficiency
Anemia in Pregnancy

Ferritin >30

MCV < 70

Thalassemia

Ferritin<30

Hb < 11 (1st tri)
Hb < 10.5 (2nd tri)
Hb < 11 (3rd tri)

CRP >1 mg/dL
inflammation?

Hb > 11 (1st tri)
Hb > 10.5 (2nd tri)
Hb > 11 (3rd tri)

Hb < 11 (1st tri)
Hb < 10.5 (2nd tri)
Hb < 11 (3rd tri)

Iron Deficiency

1st Trimester

Oral Iron Therapy

Iron Deficiency
Anemia

2nd and 3rd
Trimester

Oral Iron Therapy

Inadequate response
to oral iron,
noncompliance,
intolerance

IV iron therapy

Severe anemia Hb <9,
risk factors, need for
immediate correction

IV iron therapy
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D. Provider Clinic Information Flyer

Antepartum Iron
Infusion Clinic
Hours of Operation:

Location:

Mondays

Holtz ET 7th Floor, Antepartum Unit

8am – 12pm

Appointments:
Email requests to ObIron@jhsmiami.org with the following information:
1.
2.
3.
4.
5.
6.
7.
8.

Patient Name
MRN
EDD
Patient’s Contact Number
Ordering Provider
Desired Date
Desired Amount of Doses
COVID symptoms or recent positive PCR test? Yes/No

*For Uhealth patients, the referring office will be responsible for obtaining insurance authorization*
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E. Nursing In-service Presentation

OB Iron Infusion Clinic
RN In-service
Melissa Barrera, MSN, APRN, FNP- BC
Jessica Saint Clair, DNP, APRN, FNP- BC

WHAT IS IRON DEFICIENCY ANEMIA?
• Iron deficiency anemia - Iron deficiency anemia can be
defined by any one of the following findings:
o Serum ferritin <30 ng/mL
o Transferrin saturation <19 percent, mostly used in
patients for whom the ferritin is thought to be unreliable
due to an inflammatory state
o Anemia that resolves upon iron administration
o Absence of stainable iron in the bone marrow (providing
that adequate staining controls are performed)
(UpToDate, 2020)

• Anemia of pregnancy - The World Health Organization
(WHO) and the American College of Obstetricians and
Gynecologists (ACOG) define anemia in pregnancy as
follows:
o First trimester – Hemoglobin <11 g/dL
o Second trimester – Hemoglobin <10.5 g/dL
o Third trimester – Hemoglobin level <10.5 to 11 g/dL
o Postpartum – Hemoglobin 10 g/dL
(ACOG, 2020)

BACKGROUND

• Iron deficiency anemia could put pregnant
women at increased risk for preterm labor,
sepsis, and preeclampsia (Young, et. al, 2019)

• Anemia could cause intrauterine growth
disturbances, impact fetal neurodevelopment,
and could even lead to fetal loss (Young, et. al,
2019)
• The current obstacles faced in the treatment of
iron deficiency anemia include access to care.
• At Jackson Memorial, it is treated with oral iron
or intravenous iron sucrose. Many women
cannot tolerate the GI side effects related to oral
iron. In order to get IV iron, the woman is
required to essentially spend all day at the
hospital as an admitted for observation patient.
• In order to address this problem, Jackson
Memorial Women’s Hospital is implementing
an outpatient iron infusion clinic that will be
staffed by Antepartum GYN/GYO nurses!
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Challenges during clinic hours:

1.Antepartum Charge Nurse
2.APRN Coordinator: Jessica Saint Clair (85-5801)
3.MFM resident (pager #2125 or #9271)
4.Nurse Manager: Gustavo Rocha
Scheduling: Scheduling: Antepartum secretary or
email ObIron@jhsmiami.org

QUESTIONS?
Jessica Saint Clair, DNP, APRN, FNP-BC
Office #: 85-5801
Email: jessica.saintclair@jhsmiami.org
Melissa Barrera, MSN, APRN, FNP-BC
Email: melissa.barrera@jhsmiami.org
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F. Outpatient Iron Infusion Clinic Policy Draft

Outpatient Iron Infusion Clinic Policy Draft
Table of Contents
I.
II.
III.

I.

Purpose...........................................................................................................................................1
Definitions.......................................................................................................................................1
Procedure.....................................................................................................................................1-2

Purpose

Treatment of iron deficiency anemia in the antenatal and postpartum period in order to improve
maternal and fetal outcomes. Target population:
•
•
•
•
•

Pregnant patients who have not responded to oral iron supplements.
Pregnant patients with co-existing GI disorders and not candidates for oral iron.
Pregnant patients with a history of bariatric surgery.
Pregnant patients with anemia in the third trimester.
Postpartum patients with anemia and significant blood loss during delivery.

II. Definitions
Anemia is an important risk factor for both maternal and fetal morbidity. Iron deficiency anemia is
associated with higher rates of preterm birth, low birth weight, and small for gestational age
newborns. (9) Maternal risks include fatigue, pallor, tachycardia, and poor exercise tolerance. (16)
Anemia in pregnancy is defined as:
•
•
•
•
•

First Trimester: Hgb < 11 g/dL
Second Trimester: Hgb < 10.5 g/dL
Third Trimester: Hgb < 11 g/dL
Ferritin < or = 30 mg/L
MCV < 80-96 fL/red cell

III. Procedure
Materials:
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o
o
o
o
o
o
o

Normal saline 250mL for mainline IV
1 IV infusion set, 1 secondary line set
IV catheter 18G or 20G
Medication labels
Antiseptic swabs
Infusion pump
Iron sucrose pre-mixed 100mL

Medication Administration:
1.
2.
3.
4.
5.
6.
7.

Establish IV access
Prime infusion set with normal saline
Piggy back iron sucrose pre-mixed 100mL
Program infusion pump to deliver iron sucrose over 30 minutes
Follow infusion with remaining normal saline
Discontinue infusion
Discontinue IV access

Maternal/ Fetal Monitoring:
o
o
o

Prior to infusion: Perform vital signs and fetal heart rate
Following infusion: Perform vital signs and fetal heart rate
If any concerns, escalate to OB team and transport to OB triage for further evaluation

Adverse Reactions:
o
o

Immediately discontinue infusion and notify provider
Administer Benadryl 25mg as ordered by MD for any adverse reactions
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G. Material Safety Data Sheets

Venofer® Iron Sucrose Injection, USP
Safety Data Sheet
according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations
Revision Date: 01/10/2019 Date of issue: 08/26/2014

Version: 1.0

SECTION 1: IDENTIFICATION
1.1.

Product Identifier

Product Form: Colloidal Solution
Product Name: Venofer® (Iron Sucrose Injection, USP)
Product Codes: 0517-2340-01; 0517-2340-10; 0517-2340-25; 0517-2325-10; 0517-2310-05; 0517-2340-99

1.2.

Intended Use of the Product

Use of the substance/mixture: An iron replacement product indicated for the treatment of iron deficiency anemia in patients
with chronic kidney disease (CKD).

1.3.

Name, Address, and Telephone of the Responsible Party

Company
American Regent, Inc.
5 Ramsey Road
P.O. Box 9001
Shirley, NY
1-800-645-1706
www.americanregent.com

1.4.

Emergency Telephone Number

Emergency Number

: CHEMTREC 1-800-424-9300

SECTION 2: HAZARDS IDENTIFICATION
2.1.
Classification of the Substance or Mixture
Classification (GHS-US)
Not classified

2.2.
Label Elements
GHS-US Labeling
No labeling applicable

2.3.

Other Hazards

Other Hazards: Exposure may aggravate individuals with iron overload. The most common adverse reactions are diarrhea,
nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, chest pain,
and peripheral edema. Hemosiderosis has been observed following overdosage. Refer to package insert for more information.
2.4.
Unknown Acute Toxicity (GHS-US) No data available

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS
3.1.
3.2.

Substance Not applicable
Mixture

Name
Water for Injection
Saccharated iron oxide
Sodium hydroxide

Product identifier
(CAS No) 7732-18-5
(CAS No) 8047-67-4
(CAS No) 1310-73-2

%
qs
2% w/v Iron (Fe)
Used to adjust pH

Classification (GHS-US)
Not classified
Not classified
Met. Corr. 1, H290
Acute Tox. 4 (Dermal), H312
Skin Corr. 1A, H314
Eye Dam. 1, H318
Aquatic Acute 3, H402

Full text of H-phrases: see section 16

SECTION 4: FIRST AID MEASURES
4.1.

Description of First Aid Measures

First-aid Measures General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice
(show the label where possible).
First-aid Measures After Inhalation: Go into open air and ventilate suspected area. Seek medical attention.
First-aid Measures After Skin Contact: Remove contaminated clothing. Flush affected area with water for at least 15 minutes.
Seek medical attention.
First-aid Measures After Eye Contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present and
easy to do. Continue rinsing. Seek medical attention.
First-aid Measures After Ingestion: Rinse mouth. Do NOT induce vomiting. Seek medical attention.
01/10/2019

EN (English US)

1/5

IMPLEMENTATION OF AN OUTPATIENT IRON INFUSION CLINIC

SAFETY DATA SHEET
Product Name: Diphenhydramine Hydrochloride Injection
1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
Manufacturer Name And
Address

Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone
Hospira, Inc., Non-Emergency

CHEMTREC: North America: 800-424-9300;
International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
224 212-2000

Product Name

Diphenhydramine Hydrochloride Injection

Synonyms

2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride.

2. HAZARD(S) IDENTIFICATION
Emergency Overview

Diphenhydramine Hydrochloride Injection is a solution containing diphenhydramine
hydrochloride, an antihistamine used for relief of symptoms associated with allergies
or colds; it is also used for the treatment of symptoms associated with motion sickness.
In the workplace, this material should be considered potentially irritating to eyes and
the respiratory tract. Based on clinical use, possible target organs include skin, eyes,
central nervous system, and gastrointestinal system.

U.S. OSHA GHS Classification
Physical Hazards

Health Hazards

Hazard Class

Hazard Category

Not Classified

Not Classified

Hazard Class

Hazard Category

STOT – RE

2

Label Element(s)
Pictogram

Signal Word
Hazard Statement(s)
Precautionary Statement(s)
Prevention
Response

Warning
May cause damage to organs through prolonged or repeated exposure
Do not breathe vapor or spray.
Wash hands thoroughly after handling.
Get medical attention if you feel unwell.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
if present and easy to do. Continue rinsing. If eye irritation persists, get medical
attention.

1
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H. Conceptual Underpinning & Theoretical Framework Diagrams

Donabedian Model
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